The Medication Myth Your Doctor Isn't Allowed to Tell You: Why Your Prescription is Only Half the Story
You leave the doctor's office with a script in hand, a plan in mind, and hope for a cure. You take the pill faithfull...
VELCADE INJECTION 2mg Vial (Bortezomib)
$1,113.36
Active Ingredient : Bortezomib
Discover the benefits of VELCADE INJECTION 2mg Vial (Bortezomib), a powerful treatment designed to help manage multiple myeloma and certain types of lymphoma. This medication works by targeting and inhibiting proteasomes, contributing to cancer cell death
Reliable shipping
Flexible returns
Dispensing Country : India
VELCADE Injection 2mg Vial, containing the active ingredient Bortezomib, is a specialized medication primarily used in the treatment of multiple myeloma and mantle cell lymphoma. This injectable formulation is designed for intravenous or subcutaneous administration, offering flexibility in treatment options based on patient needs and medical guidance. Bortezomib works by inhibiting proteasomes, which play a critical role in cell regulation and growth, thereby targeting cancer cells and slowing disease progression.
Each VELCADE 2mg Vial is carefully manufactured to ensure precise dosing and high quality, making it a reliable choice for healthcare providers. The medication is typically administered in cycles, with the dosage and frequency determined by the patient’s condition, response to treatment, and overall health profile. It is often used in combination with other therapies to enhance its effectiveness.
Patients using VELCADE may experience side effects such as fatigue, nausea, diarrhea, or peripheral neuropathy. Regular monitoring and communication with a healthcare provider are essential to manage these side effects and adjust treatment as needed. It is crucial to follow the prescribed administration guidelines to minimize risks and maximize therapeutic benefits.
VELCADE Injection is contraindicated in patients with a known hypersensitivity to Bortezomib or any of its components. It should be used with caution in individuals with pre-existing liver or kidney conditions. Proper storage of the vials is necessary, and they should be kept at controlled room temperature, protected from light, and out of reach of children.
This medication has been widely recognized for its efficacy in improving survival rates and quality of life for patients with specific hematologic malignancies. It is an essential tool in the oncologist’s arsenal, offering hope and therapeutic benefits to those battling complex cancers.
- Bortezomib
- Mannitol
- Sodium citrate
- Hydrochloric acid
- Sodium hydroxide
- Water for injection
VELCADE INJECTION 2mg Vial (Bortezomib) is a prescription medication used to treat certain types of cancer, including multiple myeloma and mantle cell lymphoma. It is administered by a healthcare professional in a clinical setting. Below are detailed instructions for its proper use:
- Preparation: Before administration, ensure the vial is inspected for any particulate matter or discoloration. The powder should appear as a white to off-white cake. Reconstitute the vial with 2 mL of 0.9% Sodium Chloride Injection to achieve a concentration of 1 mg/mL bortezomib. Gently swirl the vial to dissolve the powder—avoid vigorous shaking.
- Dosage: The dosage is determined by the treating physician based on the patient's body surface area, medical condition, and response to treatment. The typical dose is 1.3 mg/m², administered intravenously or subcutaneously. Follow the prescribed dosing schedule strictly.
- Administration:
- For intravenous use, administer the reconstituted solution as a 3-5 second bolus injection through a peripheral or central venous catheter.
- For subcutaneous use, inject into the thigh or abdomen, rotating the injection sites to minimize irritation.
- Frequency: VELCADE is usually given twice weekly (e.g., on Days 1, 4, 8, and 11) for two weeks, followed by a 10-day rest period. This constitutes one treatment cycle. The exact schedule may vary based on the treatment plan.
- Monitoring: Patients should be closely monitored for adverse reactions, such as peripheral neuropathy, hypotension, or blood disorders. Regular blood tests are required to assess platelet counts and other parameters.
- Storage: Unopened vials should be stored at controlled room temperature (20°C-25°C) and protected from light. After reconstitution, the solution may be stored at 25°C for up to 8 hours or refrigerated at 2°C-8°C for up to 24 hours. Discard any unused portion.
- Precautions: Healthcare providers should wear gloves when handling VELCADE. Avoid contact with skin or mucous membranes. In case of accidental exposure, rinse thoroughly with water.
Always follow the specific instructions provided by the prescribing physician and refer to the official prescribing information for additional details. Do not adjust the dose or administration method without medical advice.
You may also like
Our products are sourced directly from brands or authorized distributors.
